Please ensure Javascript is enabled for purposes of website accessibility

Biogen's Alzheimer's Disease Treatment Earns FDA Approval

By Cory Renauer - Jun 7, 2021 at 12:45PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Aducanumab becomes the first available treatment intended to stop patients with Alzheimer's disease from losing more memories.

The long wait for a disease-modifying treatment option for millions of Americans suffering from Alzheimer's disease is finally over. The FDA on Monday approved aducanumab from Biogen (BIIB 3.28%) and its longtime collaboration partner Eisai (ESALY 1.38%). Biogen will market the drug under the brand name Aduhelm.

Aduhelm acts in the brain to remove amyloid protein fragments before they can form sticky plaques associated with Alzheimer's disease. Unfortunately, aducanumab failed to outperform a placebo in one of two identical clinical trials designed to prove its ability to help preserve patients' cognitive ability. Biogen also failed to convince a panel of independent experts that Aduhelm provided a disease-modifying benefit.

Elderly patient with a caregiver.

Image source: Getty Images.

However, the FDA granted Aduhelm an accelerated approval based on its ability to improve amyloid protein fragment concentrations. In theory, this approval will be rescinded if Biogen doesn't provide clinical evidence of a cognitive benefit at some point in the future. In practice, though, drugs that are granted accelerated approvals tend to remain on pharmacy shelves even when such evidence fails to materialize.

Aduhelm isn't intended for patients who have already progressed to a severe stage of Alzheimer's disease, but the FDA didn't specify disease severity on Aduhelm's prescribing label. This means there are around 6.2 million Americans now eligible to begin treatment with the drug.

Don't be surprised if sales of Aduhelm top $10 billion annually long before Biogen provides any further evidence of efficacy. Patients who receive monthly infusions of the drug will need regular MRIs to monitor for signs of dangerous brain swelling that occurred in some clinical trial participants, but the label contains no black box warnings to hinder its uptake.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Biogen Inc. Stock Quote
Biogen Inc.
BIIB
$210.63 (3.28%) $6.69
Eisai Co., Ltd. Stock Quote
Eisai Co., Ltd.
ESALY
$42.58 (1.38%) $0.58

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
311%
 
S&P 500 Returns
110%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.